美国FDA-话题@MedSci

#美国FDA#

186篇内容 | 3874人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1551422, encodeId=8b41155142277, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=HighTide制药的非酒精性脂肪性肝炎（NASH）疗法HTD1801已获得美国FDA批准, objectType=article, longId=154608, objectId=aa811546081e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa811546081e, replyNumber=0, likeNumber=68, createdTime=2018-11-30, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa811546081e, moduleTitle=HighTide制药的非酒精性脂肪性肝炎（NASH）疗法HTD1801已获得美国FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa811546081e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551421, encodeId=bf2915514214c, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=Alembic制药宣布美国FDA已正式批准其不同剂量的Temazepam胶囊, objectType=article, longId=154606, objectId=d482154606ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d482154606ea, replyNumber=0, likeNumber=65, createdTime=2018-11-30, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d482154606ea, moduleTitle=Alembic制药宣布美国FDA已正式批准其不同剂量的Temazepam胶囊, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d482154606ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551420, encodeId=bd3d15514208f, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA专家组一致同意Shire的普卢卡必利治疗慢性特发性便秘, objectType=article, longId=151514, objectId=abb1151514a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abb1151514a2, replyNumber=0, likeNumber=58, createdTime=2018-10-23, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abb1151514a2, moduleTitle=美国FDA专家组一致同意Shire的普卢卡必利治疗慢性特发性便秘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abb1151514a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551419, encodeId=92dc1551419f9, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA批准新型抗菌药物治疗严重肺病, objectType=article, longId=149989, objectId=a8e514998999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8e514998999, replyNumber=0, likeNumber=85, createdTime=2018-10-01, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8e514998999, moduleTitle=美国FDA批准新型抗菌药物治疗严重肺病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8e514998999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551418, encodeId=cfdd155141892, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA批准VIZIMPRO用于EGFR突变的转移性非小细胞肺癌的一线治疗, objectType=article, longId=149975, objectId=90091499e58a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90091499e58a, replyNumber=0, likeNumber=54, createdTime=2018-09-30, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90091499e58a, moduleTitle=美国FDA批准VIZIMPRO用于EGFR突变的转移性非小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90091499e58a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551417, encodeId=9758155141e7e, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=强生就Erdafitinib向美国FDA提交了新药申请, objectType=article, longId=149159, objectId=e1751491599c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1751491599c, replyNumber=0, likeNumber=74, createdTime=2018-09-21, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1751491599c, moduleTitle=强生就Erdafitinib向美国FDA提交了新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1751491599c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551416, encodeId=013d155141691, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA正式拒绝葛兰素史克的Nucala治疗COPD的申请, objectType=article, longId=148545, objectId=486c1485450b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=486c1485450b, replyNumber=0, likeNumber=75, createdTime=2018-09-11, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=486c1485450b, moduleTitle=美国FDA正式拒绝葛兰素史克的Nucala治疗COPD的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=486c1485450b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551415, encodeId=5d5f1551415c7, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=阿斯利康哮喘新药tezepelumab获得美国FDA突破性疗法认定, objectType=article, longId=148544, objectId=840b148544ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=840b148544ae, replyNumber=0, likeNumber=65, createdTime=2018-09-11, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=840b148544ae, moduleTitle=阿斯利康哮喘新药tezepelumab获得美国FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=840b148544ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551414, encodeId=e535155141480, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=Keytruda/Alimta联合治疗NSCLC获美国FDA批准, objectType=article, longId=147278, objectId=cb7e14e27873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb7e14e27873, replyNumber=0, likeNumber=69, createdTime=2018-08-24, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb7e14e27873, moduleTitle=Keytruda/Alimta联合治疗NSCLC获美国FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb7e14e27873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551413, encodeId=041a1551413f6, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA批准Omadacycline抗生素上市, objectType=article, longId=146516, objectId=1f8a146516ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f8a146516ba, replyNumber=0, likeNumber=83, createdTime=2018-08-14, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f8a146516ba, moduleTitle=美国FDA批准Omadacycline抗生素上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f8a146516ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551412, encodeId=ec1e1551412ed, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA授予BioCryst的BCX7353快速通道资格, objectType=article, longId=146061, objectId=37d3146061bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37d3146061bc, replyNumber=0, likeNumber=49, createdTime=2018-08-08, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37d3146061bc, moduleTitle=美国FDA授予BioCryst的BCX7353快速通道资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37d3146061bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551411, encodeId=9617155141127, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA咨询委员会投票支持Tafenoquine预防疟疾, objectType=article, longId=145484, objectId=e29e14548485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e29e14548485, replyNumber=0, likeNumber=0, createdTime=2018-07-31, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e29e14548485, moduleTitle=美国FDA咨询委员会投票支持Tafenoquine预防疟疾, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e29e14548485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551410, encodeId=e7d01551410b5, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=未来已来！美国FDA发布6大指南高调“护航”基因疗法, objectType=article, longId=144852, objectId=3f3614485219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f3614485219, replyNumber=0, likeNumber=74, createdTime=2018-07-22, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f3614485219, moduleTitle=未来已来！美国FDA发布6大指南高调“护航”基因疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f3614485219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551409, encodeId=92281551409b8, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=Science：用数据揭露，美国FDA新药审核员与药企之间不得不说的“暧昧”, objectType=article, longId=144255, objectId=1e061442554c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e061442554c, replyNumber=0, likeNumber=71, createdTime=2018-07-14, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e061442554c, moduleTitle=Science：用数据揭露，美国FDA新药审核员与药企之间不得不说的“暧昧”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e061442554c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551408, encodeId=fd0b1551408c1, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA批准人工虹膜有望解决患者困扰, objectType=article, longId=139676, objectId=0a971396e687, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a971396e687, replyNumber=0, likeNumber=58, createdTime=2018-06-02, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a971396e687, moduleTitle=美国FDA批准人工虹膜有望解决患者困扰, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a971396e687)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551407, encodeId=b1c4155140e93, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=JCO：精准肿瘤学时代--美国FDA在准入与安全之间找平衡, objectType=article, longId=137960, objectId=b3c213e960f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3c213e960f5, replyNumber=0, likeNumber=81, createdTime=2018-05-13, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3c213e960f5, moduleTitle=JCO：精准肿瘤学时代--美国FDA在准入与安全之间找平衡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3c213e960f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551406, encodeId=83a61551406be, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA批准奥拉帕利用于治疗携带BRCA基因突变的 HER2阴性转移性乳腺癌患者, objectType=article, longId=126913, objectId=7292126913f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7292126913f3, replyNumber=0, likeNumber=84, createdTime=2018-01-20, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7292126913f3, moduleTitle=美国FDA批准奥拉帕利用于治疗携带BRCA基因突变的 HER2阴性转移性乳腺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7292126913f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551405, encodeId=008d155140583, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=2017美国FDA哪五大举措足以影响未来？, objectType=article, longId=125697, objectId=707b12569ea4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=707b12569ea4, replyNumber=0, likeNumber=82, createdTime=2018-01-07, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=707b12569ea4, moduleTitle=2017美国FDA哪五大举措足以影响未来？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=707b12569ea4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551404, encodeId=e51f1551404fd, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=2017年美国FDA获批的非小细胞肺癌新药, objectType=article, longId=125527, objectId=c3e012552e4b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3e012552e4b, replyNumber=0, likeNumber=35, createdTime=2018-01-06, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3e012552e4b, moduleTitle=2017年美国FDA获批的非小细胞肺癌新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3e012552e4b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551403, encodeId=00e21551403f4, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=**双药HIV疗法今日获美国FDA批准, objectType=article, longId=121083, objectId=dc9912108308, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc9912108308, replyNumber=0, likeNumber=87, createdTime=2017-11-24, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc9912108308, moduleTitle=**双药HIV疗法今日获美国FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc9912108308)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

美国FDA

2020-05-29

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

HighTide制药的非酒精性脂肪性肝炎（NASH）疗法HTD1801已获得美国FDA批准

2018-11-30

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

Alembic制药宣布美国FDA已正式批准其不同剂量的Temazepam胶囊

2018-11-30

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA专家组一致同意Shire的普卢卡必利治疗慢性特发性便秘

2018-10-23

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA批准新型抗菌药物治疗严重肺病

2018-10-01

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA批准VIZIMPRO用于EGFR突变的转移性非小细胞肺癌的一线治疗

2018-09-30

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

强生就Erdafitinib向美国FDA提交了新药申请

2018-09-21

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA正式拒绝葛兰素史克的Nucala治疗COPD的申请

2018-09-11

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

阿斯利康哮喘新药tezepelumab获得美国FDA突破性疗法认定

2018-09-11

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

Keytruda/Alimta联合治疗NSCLC获美国FDA批准

2018-08-24

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA批准Omadacycline抗生素上市

2018-08-14

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA授予BioCryst的BCX7353快速通道资格

2018-08-08

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA咨询委员会投票支持Tafenoquine预防疟疾

2018-07-31

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

未来已来！美国FDA发布6大指南高调“护航”基因疗法

2018-07-22

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

Science：用数据揭露，美国FDA新药审核员与药企之间不得不说的“暧昧”

2018-07-14

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA批准人工虹膜有望解决患者困扰

2018-06-02

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

JCO：精准肿瘤学时代--美国FDA在准入与安全之间找平衡

2018-05-13

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA批准奥拉帕利用于治疗携带BRCA基因突变的 HER2阴性转移性乳腺癌患者

2018-01-20

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

2017美国FDA哪五大举措足以影响未来？

2018-01-07

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

2017年美国FDA获批的非小细胞肺癌新药

2018-01-06

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

**双药HIV疗法今日获美国FDA批准

2017-11-24

科室
- - 订阅+
  - 更多科室
工具
服务